Health Condition 1: L400- Psoriasis vulgaris
Conditions
Interventions
Intervention1: UNIM 401 & UnIM 402: UNIM 401 and UNIM 402 will be given to the psoriasis patients for 6 weeks at an interval of 15 days.
1. 17 gm of UNIM 401 in the dosage form of infusion (Khesanda)
Sponsors
CCRUM
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult of either sex between 18 and 65 years who diagnosed with psoriasis with or without metabolic syndrome 2. On no regular medical treatment 3. Able to communicate effectively with study personnel 4. Able to be informed of the nature of the study and willing to give written informed consent
Exclusion criteria
Exclusion criteria: Pregnant and lactating mothers Patients with previous serious adverse effects to Herbal drugsPatients with renal, hepatic, other dermatological disease or severe cardiac disease. Patient with personal or family history of pre-malignant or malignant skin tumors. Patient unsure about attending treatment schedule regularly Patients who have received systemic therapy for psoriasis or those who have been treated with immunosuppressive/immunomodulating treatment in previous 14 days. Patients not willing to give consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The severity of the psoriasis disease will be assessed through PASI score at an interval of 15 days up to 6 weeks and the other laboratory parameters i.e Serum CRP, Uric acid levels, waist circumference, blood pressure, fasting blood glucose, triglycerides, or HDL cholesterol will be assessed at baseline and end of study. The decrease in PASI score, Uric acid, serum CRP , if any, point out the validation of therapeutic efficacy of UNIM 401 and UNIM 402Timepoint: 6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| The assessment of the PASI score, CRP & uric acid with markers of metabolic syndrome i.e waist circumference, blood pressure, fasting blood glucose, triglycerides, or HDL cholesterol at baseline & end of the study (after 6 week ) will help in resolving the issue whether higher level of serum CRP & Uric acid in patients is directly associated with psoriasis disease or indirectly due to the association of metabolic syndrome with psoriasis Timepoint: 6 weeks | — |
Countries
India
Contacts
Public ContactDr Kishore Kumar
Regional Research Institute of Unani Medicine Bhadrak
Outcome results
None listed